A Rollover Study to Evaluate Safety and Therapeutic Effect of Re-Infusing Subjects Who Completed Participation in the VRX496-USA-05-002 Trial With Autologous T Cells Transduced With VRX496 [lexgenleucel-T].
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2010
At a glance
- Drugs Lexgenleucel T (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 05 Oct 2010 Planned end date changed from 1 Mar 2010 to 1 Jun 2023 as reported by ClinicalTrials.gov.
- 05 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.